CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: A case-control study

Pharmacogenetics and Genomics

Volumn 26, Issue 2, 2016, Pages 66-73

  Figueiras, A ^h   Estany Gestal, A ^h   Aguirre, C ^h   Ruiz, B ^h   Vidal, X ^h   Carvajal, A ^h   Salado, Inés ^f   Salgado Barreira, A ^h   Rodella, Luca ^g   Moretti, Ugo ^g   Ibanez L ^h   Lopez P ^h   Sanchez Diz P ^h   Ruano, A ^h   Dominguez E ^h   Ortega, S ^h   De Pancorbo, M M ^h   Ruiz, P ^h   Conforti, A ^h   Leone, R ^h  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c HOSPITAL DE GALDAKAO   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF VALLADOLID   (Spain)

^g UNIVERSITY HOSPITAL OF VERONA   (Italy)

^h Verona University Hospital ^*  (Italy)

Author keywords

CYP2C92; CYP2C93; Gastrointestinal hemorrhage; NSAID

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CAFFEINE; CELECOXIB; CYTOCHROME P450 2C9; DICLOFENAC; IBUPROFEN; INDOMETACIN; LORNOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROTON PUMP INHIBITOR; CYP2C9 PROTEIN, HUMAN;

ADULT; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; CASE CONTROL STUDY; CONSUMER; CONTROLLED STUDY; DRUG EXPOSURE; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART DISEASE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RISK FACTOR; SINGLE BLIND PROCEDURE; SINGLE NUCLEOTIDE POLYMORPHISM; UPPER GASTROINTESTINAL BLEEDING; WILD TYPE; AGED; CHEMICALLY INDUCED; GASTROINTESTINAL HEMORRHAGE; GENETICS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2C9; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED;

EID: 84983094488     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000186     Document Type: Article

References (45)

1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329:15-19.
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340:1888-1899.
3. Green GA. Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone 2001; 3:50-60.
4. Laporte JR, Ibáñez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004; 27:411-420.
5. Miners JO, Birkett DJ. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45:525-538.
6. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116:496-526.
7. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77:1-16.
8. Sánchez-Diz P, Estany-Gestal A, Aguirre C, Blanco A, Carracedo A, Ibáñez L, et al. Prevalence of CYP2C9 polymorphisms in the south of Europe. Pharmacogenomics J 2009; 9:306-310.
9. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12:251-263.
10. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: Ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54:1257-1270.
11. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364:1144-1153.
12. Agúndez JA, García-Martín E, Martínez C. Genetically based impairment in CYP2C8- And CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol 2009; 5:607-620.
13. Martin JH, Begg EJ, Kennedy MA, Roberts R, Barclay ML. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br J Clin Pharmacol 2001; 51:627-630.
14. Vonkeman HE, van de Laar MA, van der Palen J, Brouwers JR, Vermes I. Allele variants of the cytochrome P450 2C9 genotype in white subjects from the Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. Clin Ther 2006; 28:1670-1676.
15. Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: Role of cytochrome P450 2C9 polymorphisms. Gastroenterology 2007; 133:465-471.
16. Ma J, Yang XY, Qiao L, Liang LQ, Chen MH. CYP2C9 polymorphism in nonsteroidal anti-inflammatory drugs-induced gastropathy. J Dig Dis 2008; 9:79-83.
17. Blanco G, Martínez C, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, et al. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet Genomics 2008; 18:37-43.
18. Carbonell N, Verstuyft C, Massard J, Letierce A, Cellier C, Deforges L, et al. CYP2C9∗3 loss-of-function allele is associated with acute upper gastrointestinal bleeding related to the use of NSAIDs other than aspirin. Clin Pharmacol Ther 2010; 87:693-698.
19. Estany-Gestal A, Salgado-Barreira A, Sánchez-Diz P, Figueiras A. Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: A systematic critical review. Pharmacogenet Genomics 2011; 21:357-364.
20. Rothman KJ, Greenland S. Modern epidemiology, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998. p. 119.
21. Lanas A, Bajador E, Serrano P, Fuentes J, Carreño S, Guardia J, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343:834-839.
22. Laporte JR, Carné X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal antiinflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet 1991; 337:85-89.
23. TrinityBiotech. Helicobacter pylori test. Available at: http://www.trinitybiotech.com/products/uni-gold-h-pylori-antigen/. [Accessed 11 February 2009].
24. Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: A systematic review and meta-analysis. Am J Gastroenterol 2006; 101:848-863.
25. WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. Definition and general considerations. Available at: http://www.whocc.no/ddd/definition-and-general-considera/. [Accessed 1 May 2012].
26. Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy-Weinberg equilibrium in genetic association studies: An empirical evaluation of reporting, deviations, and power. Eur J Hum Genet 2005; 13:840-848.
27. Chen J, Chatterjee N. Exploiting Hardy-Weinberg equilibrium for efficient screening of single SNP associations from case-control studies. Hum Hered 2007; 63:196-204.
28. Puehringer H, Loreth RM, Klose G, Schreyer B, Krugluger W, Schneider B, Oberkanins C. VKORC1 -1639G>A and CYP2C9∗3 are the major genetic predictors of phenprocoumon dose requirement. Eur J Clin Pharmacol 2010; 66:591-598.
29. Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Güzelbey P, Ongen Z, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48:409-415.
30. González JR, Armengol L, Guinó E, Solé X, Moreno V. SNPassoc: SNPsbased whole genome association studies. R package version 1.6-0; 2009. Available at: http://CRAN.R-project.org/[Accessed 3 September 2012].
31. Liu L, Shao JH, Wang K, Hua FZ. Methodological concerns about a recent meta-analysis of the influence of the I148M variant of patatin-like phospholipase domain containing 3 on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53:2145.
32. Brown H, Prescott R. Applied mixed models in medicine, 2nd ed. New Jersey: John Wiley and Sons; 2006. pp. 320-321.
33. Bates D, Sarkar D. lme4: linear mixed-effects models using S4 classes. R package version 0.999375-26; 2007. Available at: http://CRAN.R-project.org/. [Accessed 30 May 2012].
34. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129:125-137.
35. Schwarz G. Estimating the dimension of a model. Ann Stat 1978; 6:461-464.
36. Figueiras A, Domenech-Massons JM, Cadarso C. Regression models: calculating the confidence interval of effects in the presence of interactions. Stat Med 1998; 17:2099-2105.
37. Skrondal A. Interaction as departure from additivity in case-control studies: A cautionary note. Am J Epidemiol 2003; 158:251-258.
38. McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: An examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013; 10:e1001388.
39. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-1698.
40. Liu X, Fallin MD, Kao WH. Genetic dissection methods: Designs used for tests of gene-environment interaction. Curr Opin Genet Dev 2004; 14:241-245.
41. Albert PS, Ratnasinghe D, Tangrea J, Wacholder S. Limitations of the caseonly design for identifying gene-environment interactions. Am J Epidemiol 2001; 154:687-693.
42. Musumba CO, Jorgensen A, Sutton L, Van Eker D, Zhang E, O'Hara N, et al. CYP2C19∗17 gain-of-function polymorphism is associated with peptic ulcer disease. Clin Pharmacol Ther 2013; 93:195-203.
43. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003; 361:598-604.
44. Lee WC, Wang LY. Simple formulas for gauging the potential impacts of population stratification bias. Am J Epidemiol 2008; 167:86-89.
45. Chang SY, Li W, Traeger SC, Wang B, Cui D, Zhang H, et al. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+ )- And (R)- (-)-ibuprofen hydroxylation in vitro. Drug Metab Dispos 2008; 36:2513-2522.